Patents by Inventor Shahrooz Rabizadeh

Shahrooz Rabizadeh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Microbial synthesis of aldehydes and corresponding alcohols
    Patent number: 10450589
    Abstract: An improved process for alcohol production includes microbial fermentation using a genetically modified microorganism to produce substantial quantities of aldehydes that are stripped from the fermentation medium and condensed. So produced aldehydes are converted in an ex vivo process to corresponding alcohols.
    Type: Grant
    Filed: June 11, 2017
    Date of Patent: October 22, 2019
    Assignee: Easel Biotechnologies, LLC
    Inventors: Wendy M. Higashide, Kwang Myung Cho, Shahrooz Rabizadeh
  • Compositions and methods of improved wound healing
    Patent number: 10434142
    Abstract: Compositions and methods are contemplated for treatment of a wound, and especially a sterile or TLR/NOD ligand-poor wound in which contemporaneous administration of a Ca2+-flux agonist (CFA) and a pattern recognition receptor (PRR) ligand improves wound healing.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: October 8, 2019
    Assignee: Chan Soon-Shiong Nanthealth Foundation
    Inventors: Kayvan Niazi, Shahrooz Rabizadeh, Justin Golovato, Oleksandr Buzko, Anne-Laure Le Ny, Patrick Soon-Shiong
  • METHODS AND ARTIFICIAL TUMORS FOR VALIDATING AN ANTITUMOR IMMUNE RESPONSE
    Publication number: 20190285615
    Abstract: The invention provides methods for validating an antitumor response by growing and maintaining artificial 3D tumors under conditions that replicate the microenvironment of the naturally occurring parent tumor as found, in situ, in a subject diagnosed with a tumor or cancer. The artificial 3D tumors are obtained from the subject and once established are tested for susceptibility to proposed anticancer treatments, such as treatments personalized to the subject.
    Type: Application
    Filed: December 14, 2017
    Publication date: September 19, 2019
    Applicants: NantBio, Inc., Nant Holdings IP, LLC
    Inventors: Shahrooz RABIZADEH, Kayvan NIAZI, Nicholas J. WITCHEY
  • Microbial production of fuel components from low-molecular weight gas mixtures
    Patent number: 10385366
    Abstract: Systems, methods, and metabolically engineered microorganisms are contemplated in which low molecular weight gases, and especially methane and syngas are used as a carbon source, and in which CO2 or formaldehyde and reduction equivalents are generated for use in in vivo production of the value products.
    Type: Grant
    Filed: October 11, 2018
    Date of Patent: August 20, 2019
    Assignee: Easel Biotechnologies, LLC
    Inventors: Yi-Xin Huo, Lars Erik Ulf Rohlin, Shahrooz Rabizadeh
  • Carbon dioxide fixation via bypassing feedback regulation
    Patent number: 10385328
    Abstract: Genetically engineered cells and methods are presented that allow for the production of various value products from CO2. Contemplated cells have a CBB cycle that is genetically modified such that two molecules of CO2 fixed in the CBB cycle can be withdrawn from the modified CBB cycle as a single C2 compound. In contemplated aspects a CBB cycle includes an enzymatic activity that generates the single C2 compound from a compound of the CBB cycle, while further modifications to the CBB cycle will not introduce additional recombinant enzymatic activity/activities outside the already existing catalytic activities in the CBB cycle.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: August 20, 2019
    Assignee: Easel Biotechnologies, LLC
    Inventors: Yi-Xin Huo, Benjamin Schilling, Shahrooz Rabizadeh
  • BAM SIGNATURES FROM LIQUID AND SOLID TUMORS AND USES THEREFOR
    Publication number: 20190249229
    Abstract: Treatment of a patient diagnosed with cancer is monitored by comparing sequence data from liquid biopsies obtained during and/or after treatment with tumor and patient specific sequence data from a solid tumor obtained prior to treatment.
    Type: Application
    Filed: February 12, 2018
    Publication date: August 15, 2019
    Inventors: Patrick Soon-Shiong, Shahrooz Rabizadeh
  • BIOMARKERS IN DE NOVO PYRIMIDINE SYNTHESIS PATHWAYS AND CHEMORESISTANCE
    Publication number: 20190233900
    Abstract: Compositions, methods, and uses of de novo pyrimidine synthesis pathway element, CAD, and optionally a second gene in a nucleotide excision repair pathway, POLD2 in determining a predicted survival rate, predicted responsiveness to a cisplatin-based chemotherapy of a patient diagnosed with bladder urothelial carcinoma are provided.
    Type: Application
    Filed: January 31, 2019
    Publication date: August 1, 2019
    Inventors: Kevin B. Givechian, Chad Garner, Hermes J. Garban, Shahrooz Rabizadeh, Patrick Soon-Shiong
  • IMMUNOTHERAPY MARKERS AND USES THEREFOR
    Publication number: 20190237196
    Abstract: Systems and methods for prediction of the treatment outcome for immune therapy are presented in which omics data of a patient tumor sample are used. Most typically, the omics data are processed to identify mutational signatures (especially APOBEC/POLE signatures), immune checkpoint expression, and MSI status as leading indicators to predict the treatment outcome for immune therapy. Such prediction advantageously integrates various parameters that would otherwise, when individually considered, skew prediction outcome.
    Type: Application
    Filed: August 25, 2017
    Publication date: August 1, 2019
    Inventors: Andrew Nguyen, John Zachary Sanborn, Shahrooz Rabizadeh
  • PROTEOMICS ANALYSIS AND DISCOVERY THROUGH DNA AND RNA SEQUENCING, SYSTEMS AND METHODS
    Publication number: 20190226034
    Abstract: Specific mutations of FGFR3 (S249C) and of TP53 (V272M) are identified as being characteristic of breast cancer, and of having utility in diagnosis and prognosis of an individual with breast cancer. Systems and methods useful for identification of such mutations are also presented.
    Type: Application
    Filed: March 29, 2019
    Publication date: July 25, 2019
    Applicant: NantOmics, LLC
    Inventors: Shahrooz Rabizadeh, Patrick Soon-Shiong, Stephen Charles Benz
  • Small molecule inhibitors of influenza A RNA-dependent RNA polymerase
    Patent number: 10350225
    Abstract: Compositions, compounds, and methods with significant antiviral effect against RNA viruses and especially orthomyxoviruses are contemplated, and target the viral promoter that is formed by the 5? and 3?-UTR sequences of the viral genome.
    Type: Grant
    Filed: August 23, 2018
    Date of Patent: July 16, 2019
    Assignee: Nant Holdings IP, LLC
    Inventors: Kayvan Niazi, Shahrooz Rabizadeh, Anne-Laure Le Ny, Oleksandr Buzko, Justin Golovato, Patrick Soon-Shiong
  • Compositions and methods for reduction of allograft recognition and rejection
    Patent number: 10344280
    Abstract: Allograft recognition and rejection of donor cells in a host is reduced by limiting or even abrogating expression of the donor cell's MHC-I peptides to avoid CD8+ T-cell recognition and by expression of inhibitory factors to avoid an NK cell mediated cytotoxic response.
    Type: Grant
    Filed: August 22, 2017
    Date of Patent: July 9, 2019
    Assignee: NANT HOLDINGS IP, LLC
    Inventors: Kayvan Niazi, Shahrooz Rabizadeh, Patrick Soon-Shiong
  • METHODS AND COMPOSITIONS RELATED TO ANTIGEN PRESENTING PROTEINS
    Publication number: 20190202890
    Abstract: In some aspects, the invention relates to a transmembrane protein comprising an extracellular domain that may be cleaved from a transmembrane domain by a protease. The extracellular domain may be the extracellular domain of an antigen-presenting protein, such as CD1a.
    Type: Application
    Filed: May 20, 2016
    Publication date: July 4, 2019
    Inventors: Kayvan R. Niazi, Robert L. Modlin, Shahrooz Rabizadeh
  • Proteomics analysis and discovery through DNA and RNA sequencing, systems and methods
    Patent number: 10323285
    Abstract: Specific mutations of FGFR3 (S249C) and of TP53 (V272M) are identified as being characteristic of breast cancer, and of having utility in diagnosis and prognosis of an individual with breast cancer. Systems and methods useful for identification of such mutations are also presented.
    Type: Grant
    Filed: September 9, 2014
    Date of Patent: June 18, 2019
    Assignee: NANTOMICS, LLC
    Inventors: Shahrooz Rabizadeh, Patrick Soon-Shiong, Stephen Charles Benz
  • Subcutaneous Delivery of Adenovirus with Dual Targeting
    Publication number: 20190091316
    Abstract: Immunotherapeutic methods and compositions are contemplated in which neoepitopes and/or tumor associated antigens are delivered to dendritic cells via an adenoviral expression system that targets MHC-I and/or MHC-II presentation systems and that further provides one or more recombinant peptides to stimulate T cell activation and interfere with checkpoint inhibition. Treatment is further supported by transfusion of NK cells, which may be modified to have a high affinity CD 16 receptor and/or a chimeric antigen receptor that binds to one or more neoepitopes and/or tumor associated antigens.
    Type: Application
    Filed: February 12, 2017
    Publication date: March 28, 2019
    Inventors: Patrick Soon-Shiong, Kayvan Niazi, Shahrooz Rabizadeh
  • NK Cells with Altered CXCL12/CXCR4 Signaling
    Publication number: 20190083533
    Abstract: NK cell based cancer immunotherapy, and particularly genetically modified NK92 cell-based immunotherapy is enhanced by expression CXCL12 and/or by suppression or deletion of CXCR4 in the natural killer cells to so reduce aggregation, rejection, and/or fratricide of the natural killer cells.
    Type: Application
    Filed: January 25, 2017
    Publication date: March 21, 2019
    Inventors: Patrick Soon-Shiong, Shahrooz Rabizadeh, Kayvan Niazi
  • Compositions and Methods for Recombinant CXADR Expression
    Publication number: 20190046570
    Abstract: Recombinant expression of CXADR in a cell, and especially an immune competent cell is employed to enable or improve gene delivery to the cell by an adenovirus. In particularly preferred aspects, the immune competent cell is a an NK cell, a T-cell, a B-cell, a macrophage, or a dendritic cell, and the gene delivery comprises a recombinant nucleic acid encoding a disease-specific antigen, such as a patient specific neoepitope or a tumor associated antigen.
    Type: Application
    Filed: February 3, 2017
    Publication date: February 14, 2019
    Inventors: Patrick Soon-Shiong, Shahrooz Rabizadeh, Kayvan Niazi
  • Microbial Production Of Fuel Components From Low-Molecular Weight Gas Mixtures
    Publication number: 20190040421
    Abstract: Systems, methods, and metabolically engineered microorganisms are contemplated in which low molecular weight gases, and especially methane and syngas are used as a carbon source, and in which CO2 or formaldehyde and reduction equivalents are generated for use in in vivo production of the value products.
    Type: Application
    Filed: October 11, 2018
    Publication date: February 7, 2019
    Inventors: Yi-Xin Huo, Lars Erik Ulf Rohlin, Shahrooz Rabizadeh
  • High-Throughput Identification of Patient-Specific Neoepitopes As Therapeutic Targets For Cancer Immunotherapies
    Publication number: 20190034582
    Abstract: Systems and methods are presented that allow for selection of tumor neoepitopes that are filtered for various criteria. In particularly contemplated aspects, filtering includes a step in which the mutation leading to the neoepitope is ascertained as being located in a cancer driver gene.
    Type: Application
    Filed: February 10, 2017
    Publication date: January 31, 2019
    Inventors: Andrew Nguyen, John Zachary Sanborn, Steven Charles Benz, Kayvan Niazi, Shahrooz Rabizadeh, Patrick Soon-Shiong, Charles Joseph Vaske
  • Integrated Analysis To Determine Prognosis After Treatment For Primary Breast Cancer
    Publication number: 20190018017
    Abstract: Various protein markers can be used as post-treatment relapse predictors in HER2 positive breast cancer. Notably, these markers appear to be independent of the size of the tumor, metastasis status, grade, and hormone receptor status. In addition, HER2 quantities were in large part not correlated with likelihood of relapse.
    Type: Application
    Filed: December 11, 2016
    Publication date: January 17, 2019
    Applicants: NantOmics, LLC, Nant Holdings IP, LLC
    Inventors: Stephen Charles Benz, Todd Hembrough, Shahrooz Rabizadeh, John Zachary Sanborn, Charles Joseph Vaske, Fabiola Cecchi, Peter Fasching, Patrick Soon-Shiong
  • Systems, methods, and compositions for viral-associated tumors
    Patent number: 10176295
    Abstract: Contemplated systems and methods employ chimeric reference sequences that include a plurality of viral genome sequences to identify/quantify integration and co-amplification events. Most typically, the viral genome sequences are organized in the chimeric reference sequences as single chromosomes and the chimeric reference sequences are in BAM format.
    Type: Grant
    Filed: September 26, 2014
    Date of Patent: January 8, 2019
    Assignees: Five3 Genomics, LLC, Nant Holdings IP, LLC
    Inventors: John Zachary Sanborn, Charles Joseph Vaske, Stephen Charles Benz, Shahrooz Rabizadeh, Nicole Hensley, Patrick Soon-Shiong